Gastrointestinal
Treatment options for Crohn’s disease expand after Rinvoq approval
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not…
Leading innovators in lactobacilli-based drug compositions for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,…
Takeda to acquire Nimbus Therapeutics’ allosteric TYK2 inhibitor
Takeda has entered an agreement for the acquisition of Nimbus Therapeutics’ allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858. An oral therapy, NDI-034858 is…
NICE recommends BMS’ combination therapy for gastroesophageal cancer
The National Institute for Health and Care Excellence (NICE) in the UK has recommended Bristol Myers Squibb’s (BMS) nivolumab (Opdivo) plus chemotherapy…
EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease
The European Commission (EC) has granted approval for AbbVie’s Skyrizi (risankizumab, 600mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) to…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Rare Disease Spotlight- Oncology therapies dominate the orphan drug landscape
Rare diseases affect only a small percentage of the population, and since their pathophysiology has historically been poorly studied, there…
US FDA grants approval for Azurity’s Konvomep to treat gastric ulcer
The US Food and Drug Administration (FDA) has granted approval for Azurity Pharmaceuticals’ Konvomep (omeprazole and sodium bicarbonate for oral suspension) to…
GentiBio and BMS partner to develop inflammatory bowel disease therapies
GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory…
EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
The European Commission (EC) has granted approval for AbbVie’s Rinvoq (upadacitinib) to treat moderate-to-severe active ulcerative colitis (UC) in adult…
Takeda announces 11.6% reported revenue growth in FY2021
Takeda has recorded an 11.6% rise in its reported revenue to $27.4bn (JPY3,569bn) during the fiscal year 2021 (FY2021) compared to $24.6bn…